Search Results
Your search for Matthew Stenger matches 7475 pages
Showing 1501 - 1550Addition of Ivosidenib to Azacitidine in Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia
In the phase III AGILE trial reported in The New England Journal of Medicine, Montesinos et al found that the addition of ivosidenib to azacitidine in induction therapy significantly prolonged event-free survival in patients with newly diagnosed IDH1-mutated acute myeloid leukemia. An overall...
Switch to Maintenance Endocrine Therapy Plus Bevacizumab After First-Line Paclitaxel/Bevacizumab Induction in Advanced Estrogen Receptor–Positive, HER2-Negative Breast Cancer
In the Japanese phase II BOOSTER trial reported in The Lancet Oncology, Saji et al found that compared with continuing paclitaxel/bevacizumab, a maintenance strategy of switching to endocrine therapy plus bevacizumab (with the option of reinitiating paclitaxel/bevacizumab) was associated with a...
Improved Long-Term Quality-of-Life Measures in Women Undergoing Breast Conservation vs Mastectomy and Reconstruction for Early Breast Cancer
In a study reported in JAMA Surgery, Hanson et al found no difference in long-term satisfaction with breasts among women with early breast cancer who underwent breast-conserving surgery with radiation therapy vs mastectomy and breast reconstruction without radiation therapy. Women who underwent...
Preoperative Radiotherapy and DIEP Flap Reconstruction in Women Requiring Mastectomy for Breast Cancer
In the PRADA study—reported by Thiruchelvam et al in The Lancet Oncology—researchers found that a strategy of preoperative radiotherapy and deep inferior epigastric perforator (DIEP) flap reconstruction was feasible and safe in women requiring mastectomy for breast cancer. As stated by the...
Overall Survival in the ARCHES Trial: Addition of Enzalutamide to ADT for Metastatic Hormone-Sensitive Prostate Cancer
As reported in the Journal of Clinical Oncology by Andrew J. Armstrong, MD, ScM, and colleagues, the final overall survival analysis of the phase III ARCHES trial showed a significant benefit with the addition of enzalutamide to androgen-deprivation therapy (ADT) in patients with metastatic...
Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer
In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in patients with platinum-resistant ovarian cancer. Delta-like ligand 4 is a...
Assessment of Cancer Risk Profile for Germline BRCA1 and BRCA2 Pathogenic Variants in Patients With Common Cancers
In a Japanese case-control study reported in JAMA Oncology, Momozawa et al found that germline BRCA1/2 pathogenic variants were associated with an increased risk of biliary tract, esophageal, and gastric cancers, in addition to an increased risk of cancers that have well-established associations...
Narsoplimab for Hematopoietic Stem Cell Transplantation–Associated Thrombotic Microangiopathy
In a pivotal phase II trial reported in the Journal of Clinical Oncology, Samer K. Khaled, MD, and colleagues found that narsoplimab, an inhibitor of mannan-binding lectin-associated serine protease-2, showed efficacy in the treatment of adult patients with hematopoietic stem cell...
Addition of High-Dose Treosulfan and Melphalan to Consolidation in High-Risk Ewing Sarcoma
In a phase III trial (Ewing 2008R3) reported in the Journal of Clinical Oncology, Koch et al found that the addition of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells to consolidation did not improve event-free survival vs ...
High-Dose Radiotherapy With Short- vs Long-Term Androgen Deprivation in Localized Prostate Cancer
As reported in The Lancet Oncology by Zapatero et al, 10-year results of the Spanish phase III DART 01/05 trial did not support the 5-year findings of significantly improved biochemical disease–free, metastasis-free, and overall survival with long-term vs short-term androgen deprivation plus...
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Carcinoma
In an interim analysis of a Chinese phase III trial (FZOCUS-2) reported in the Journal of Clinical Oncology, Li et al found that maintenance treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor fuzuloparib significantly prolonged progression-free survival vs placebo in patients with...
Maternal Malignancies May Be Identified Through Noninvasive Prenatal Test Results
In a Dutch study reported in the Journal of Clinical Oncology, Heesterbeek et al found that results of noninvasive prenatal testing for fetal aneuploidy screening using cell-free DNA derived from maternal plasma raised suspicion of maternal malignancy in a very small proportion of pregnant women....
Association of Lifestyle and Cardiovascular Risk Factors With Hospitalization for Heart Failure Subtypes in Breast Cancer Survivors
In an analysis from the Women’s Health Initiative reported in JACC: CardioOncology, Kerryn W. Reding, PhD, MPH, RN, of the University of Washington at Seattle, and colleagues, identified the incidence of hospitalization for heart failure among postmenopausal breast cancer survivors. They reported...
Addition of Pembrolizumab to Chemotherapy Improves Event-Free Survival in Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, a preplanned interim analysis of the phase III KEYNOTE-522 trial has shown improved event-free survival with the addition of pembrolizumab to...
Trametinib Improves Progression-Free Survival vs Standard-of-Care Treatment in Recurrent Low-Grade Serous Ovarian Carcinoma
As reported in The Lancet by David M. Gershenson, MD, of the Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, and colleagues, the phase II/III GOG 281/LOGS trial showed that trametinib improved progression-free survival vs standard-of-care treatment...
Fixed-Dose Nivolumab and Relatlimab-rmbw for Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 18, 2022, fixed-dose nivolumab and...
Selinexor in Previously Treated Advanced Dedifferentiated Liposarcoma
In the phase II/III SEAL trial reported in the the Journal of Clinical Oncology, Gounder et al found that selinexor significantly improved progression-free survival and time to subsequent treatment in previously treated advanced dedifferentiated liposarcoma, with the greatest benefit observed in...
Overall Survival in KEYNOTE-177: Pembrolizumab vs Chemotherapy in Microsatellite Instability–High or Mismatch Repair–Deficient Metastatic Colorectal Cancer
As reported in The Lancet Oncology by Diaz et al, the final overall survival analysis of the phase III KEYNOTE-177 trial did not show a significant improvement with pembrolizumab vs chemotherapy in patients with newly diagnosed microsatellite instability–high or mismatch repair–deficient metastatic ...
CheckMate 816: Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC
As reported in The New England Journal of Medicine by Forde et al, the phase III CheckMate 816 trial has shown improved pathologic complete response rate and event-free survival with the addition of nivolumab to platinum-based chemotherapy in the neoadjuvant treatment of resectable non–small cell...
Internal Mammary Node Irradiation in Node-Positive Early Breast Cancer: 15-Year Outcomes
As reported in the Journal of Clinical Oncology by Thorsen et al, 15-year follow-up of the Danish Breast Cancer Group Internal Mammary Node study indicates continued survival benefit with internal mammary node irradiation in women with right breast tumors vs without such therapy in those with left...
Role of 21-Gene Recurrence Score and Preoperative Endocrine Therapy Response in Guiding Treatment in Early Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a German trial (WSG-ADAPT-HR1/HER2–) reported in the Journal of Clinical Oncology, Nitz et al found no difference in invasive disease-free survival between women with early hormone receptor–positive, HER2-negative breast cancer with zero to three positive nodes who had a 21-gene recurrence score ...
Addition of Nintedanib to Neoadjuvant Gemcitabine/Cisplatin in Locally Advanced Muscle-Invasive Bladder Cancer
In the UK phase II NEOBLADE trial reported in The Lancet Oncology, Hussain et al found that the addition of nintedanib to neoadjuvant gemcitabine/cisplatin did not improve pathologic complete response rate in patients with locally advanced muscle-invasive bladder cancer. In the double-blind...
PEACE-1 Trial: Addition of Abiraterone Plus Prednisone to ADT and Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer
As reported in The Lancet by Fizazi et al, the phase III PEACE-1 trial has shown that the addition of abiraterone and prednisone to androgen-deprivation therapy (ADT) and docetaxel improved radiographic progression-free survival and overall survival in patients with de novo metastatic...
Breast Cancer Screening With Digital Breast Tomosynthesis Plus Synthesized Mammography vs Digital Mammography
In the German TOSYMA trial reported in The Lancet Oncology, Heindel et al found that screening with digital breast tomosynthesis plus synthesized mammography was superior in detecting invasive breast cancer vs standard digital mammography. As stated by the investigators, “Two-dimensional (2D)...
Association of Preexisting Thyroid Autoimmunity With Risk of Papillary Thyroid Cancer
In a case-control study among U.S. active-duty personnel reported in the Journal of Clinical Oncology, McLeod et al found that preexisting thyroid autoimmunity was associated with an increased risk of developing papillary thyroid cancer. The study included 451 randomly selected personnel serving...
Race/Ethnicity Mortality Disparity in Patients With De Novo Stage IV Breast Cancer: Effect of Medicaid Expansion
In a study reported in JAMA Oncology, Malinowski et al found that Medicaid expansion resulted in a reduction in the racial and ethnic disparities in mortality among patients with de novo stage IV breast cancer. As stated by the investigators, “Patients who are uninsured and belong to racial and...
Diagnosis of Cancer Within 30 Days After Emergency Hospital Admission
In an International Cancer Benchmarking Partnership study reported in The Lancet Oncology, McPhail et al identified the proportions of cancer diagnoses made within 30 days after emergency presentation and hospital admission. They also analyzed risk factors and outcomes for such diagnoses in a group ...
Effect of Changes to California Medicaid Dental Benefits on Earlier Diagnosis of Oral Cavity Cancer
In a study reported in a research letter in JAMA Oncology, Kana et al found that changes to Medicaid dental benefits in California from comprehensive to emergency services—and then back to comprehensive—were associated with reduced, then increased, percentages of cases of oral cavity cancer...
Factors Contributing to Mortality and Second Cancer Incidence After Treatment for Testicular Cancer
In a Norwegian study reported in the Journal of Clinical Oncology, Fosså et al identified factors associated with increased mortality and second cancer risk among testicular cancer survivors, including treatment factors and modifiable adverse health outcomes. Study Details The study included data...
Association of MRD Status With Outcomes After Autologous Stem Cell Transplantation for Multiple Myeloma
In an analysis from the UK phase III MYELOMA XI trial reported in the Journal of Clinical Oncology, de Tute et al found that persistent measurable residual disease (MRD)-negative status after autologous stem cell transplantation (ASCT) and conversion from MRD-positive to -negative status were...
Longitudinal Patterns of Fatigue After Breast Cancer Diagnosis and Treatment
In an analysis from the French prospective CANTO study reported in the Journal of Clinical Oncology, Vaz-Luis et al identified three trajectory groups for the risk of severe global fatigue over time among women treated for breast cancer, consisting of a high-risk group, deteriorating group, and...
Selumetinib in Children and Young Adults With Tumors That Have Activating MAPK Pathway Alterations
In a phase II trial (arm E of the NCI-COG Pediatric MATCH trial) reported in the Journal of Clinical Oncology, Eckstein et al found that the MEK inhibitor selumetinib showed little activity in pediatric and young adult patients with tumors harboring activating MAPK pathway mutations or fusions. As...
Turnaround Times in Melanoma BRAF Testing and Effect on Time to Treatment Initiation
In a single-center study reported in JCO Oncology Practice, Ceballos et al identified turnaround times for request and receipt of melanoma BRAF testing results. They also analyzed factors in differences in turnaround times and effects on time to initiation of treatment. The study included 66...
Risk of Cardiovascular Disease and Mortality in Women With Breast Cancer: The Pathways Heart Study
In an analysis from the prospective cohort Pathways Heart Study reported in the Journal of Clinical Oncology, Heather Greenlee, ND, PhD, and colleagues found that breast cancer survivors were at increased risk of cardiovascular disease and mortality compared with women without breast cancer, with...
Biomarker-Driven Assessment of Nivolumab, Nivolumab/Ipilimumab, and VEGFR Tyrosine Kinase Inhibitors in First-Line Treatment of Metastatic Clear Cell RCC
In the French phase II BIONIKK trial reported in The Lancet Oncology, Vano et al assessed outcomes of first-line treatment with nivolumab with or without ipilimumab and VEGFR tyrosine kinase inhibitors given according to characteristics of molecular subgroups in patients with metastatic clear cell...
Association of Pretreatment Lymphocyte Count With Overall Survival and Benefit of Addition of Cisplatin to Radiotherapy in Oropharyngeal Squamous Cell Carcinoma
In a UK observational cohort study reported in the Journal of Clinical Oncology, Price et al found that pretreatment absolute lymphocyte count (ALC) was associated with overall survival and predictive of benefit of the addition of cisplatin to radiotherapy in patients with oropharyngeal squamous...
Atezolizumab Plus Bevacizumab Shows Activity in Advanced Neuroendocrine Tumors
In a single-institution phase II study reported in JAMA Oncology, Halperin et al found that the combination of atezolizumab and bevacizumab showed activity in treatment of advanced well-differentiated neuroendocrine tumors. As stated by the investigators, “Therapies for patients with advanced...
Adjuvant Pembrolizumab in Resected Stage IIB or IIC Melanoma
As reported in The Lancet by Luke et al, the phase III KEYNOTE-716 trial has shown significantly prolonged recurrence-free survival with adjuvant pembrolizumab vs placebo in patients with high-risk completely resected stage IIB/IIC melanoma at both first and second interim analyses. The first...
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
On February 28, 2022, ciltacabtagene autoleucel was approved for treatment of adults with relapsed or refractory multiple myeloma after at least four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 Ciltacabtagene autoleucel is a...
Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab Improves Progression-Free Survival in Previously Untreated Advanced Melanoma
In a phase II/III trial (RELATIVITY-047) reported in The New England Journal of Medicine, Hussein A. Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues found that the addition of relatlimab, a lymphocyte-activation gene 3 (LAG-3)–blocking antibody, to nivolumab...
Multilevel Factors Related to Changes in Body Adiposity in Black Survivors of Breast Cancer
In a study reported in the Journal of Clinical Oncology, Qin et al found that gains in body weight and body fat were common in a prospective cohort of Black breast cancer survivors. The researchers also identified factors associated with these changes. As stated by the investigators, “Unfavorable...
No Overall Survival Benefit With Atezolizumab Plus Bevacizumab vs Sunitinib in Previously Untreated Metastatic Renal Cell Carcinoma
As reported in JAMA Oncology by Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, the final overall survival analysis of the phase III IMmotion151 trial has shown no significant difference for the PD-L1 inhibitor atezolizumab plus bevacizumab vs sunitinib in patients ...
Prognostic Value of sTILs in Young Women With Node-Negative Triple-Negative Breast Cancer Who Did Not Receive (Neo)Adjuvant Systemic Therapy
In a Dutch retrospective study reported in the Journal of Clinical Oncology, de Jong et al found that higher levels of stromal tumor-infiltrating lymphocytes (sTILs) were associated with “excellent prognosis” in young women with node-negative triple-negative breast cancer who did not receive...
Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma
In the phase III TAPPAS trial reported in JAMA Oncology, Jones et al found that the addition of carotuximab to pazopanib did not improve progression-free survival in patients with advanced angiosarcoma. Carotuximab is an IgG1 antibody that binds endoglin, which is highly expressed on proliferating...
Anetumab Ravtansine vs Vinorelbine in Relapsed Mesothelin-Positive Advanced Malignant Pleural Mesothelioma
In the phase II ARCS-M trial reported in The Lancet Oncology, Hedy L. Kindler, MD, FASCO, and colleagues found that the antimesothelin antibody–tubulin inhibitor conjugate anetumab ravtansine did not improve progression-free survival vs vinorelbine as second-line treatment for patients with...
EGFR Inhibition in EGFR-Amplified Advanced Gastroesophageal Cancer
As reported in the Journal of Clinical Oncology by Maron et al, a retrospective study found that use of EGFR inhibitor therapy was associated with benefit in patients with unresectable or metastatic EGFR-amplified gastroesophageal adenocarcinoma. As stated by the investigators, “Subset analyses...
Combined BCMA and CD19 CAR T Cells in Relapsed or Refractory Multiple Myeloma: Long-Term Follow-up
In a long-term follow-up of a Chinese phase II study reported in the Journal of Clinical Oncology, Wang et al found that the combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric antigen receptor (CAR) T cells produced durable responses and favorable survival outcomes in...
Immune-Related Adverse Events With Immune Checkpoint Inhibitor Treatment for Melanoma in Older White Patients
In a population-based cohort study reported in JAMA Network Open, Schonfeld et al identified the incidence of immune-related adverse events among White patients aged ≥ 65 years with newly diagnosed melanoma treated with immune checkpoint inhibitors. They compared the risk of these adverse events...
Addition of Sorafenib to Standard Chemotherapy in Pediatric Patients With High Allelic Ratio FLT3-ITD–Positive AML
In an analysis from the Children’s Oncology Group protocol AAML1013 reported in the Journal of Clinical Oncology, Pollard et al found that the addition of sorafenib to standard chemotherapy may benefit pediatric patients with high allelic ratio FLT3-ITD–positive acute myeloid leukemia (AML). Study...
Outcomes With Pembrolizumab, Pembrolizumab/Chemotherapy, and Cetuximab/Chemotherapy by PD-L1 CPS in Recurrent/Metastatic Head and Neck Cancer
In a post hoc analysis of the KEYNOTE-048 trial reported in the Journal of Clinical Oncology, Barbara Burtness, MD, and colleagues found that survival results with pembrolizumab and pembrolizumab/chemotherapy vs cetuximab/chemotherapy in patients with recurrent or metastatic head and neck squamous...
